Cervarix, the first vaccine for cervical cancer to be approved for use in China, has passed inspection by Chinese authorities. It is currently being distributed to health centers all over the country. There are efforts in progress to spread disease awareness amongst the public as it is the third most common cancer among women ages 15 to 44. Opportunities have also been made available to train physicians on using the vaccine.
“There are about 100,000 new cases of cervical cancer in China annually, causing more than 30,000 deaths every year, according to Qiao Youlin, head of the Epidemiology Department at the Cancer Hospital, Chinese Academy of Medical Sciences, in Beijing.”
These efforts will benefit Chinese females as “Cervical cancer vaccination together with cervical cancer screening will significantly reduce the incidence.”
To read the full story, click here.